Company intelligence / Profile preview

Peptide Development Labs

Vancouver, British Columbia, Canada

Ownership: Private

Overview

Peptide Development Labs is a biotechnology company focused on the development of peptide-focused therapeutics. Spun out from HYTN Innovations in September 2026, the company's lead program is a subcutaneous injectable formulation of BPC-157, a synthetic peptide candidate being developed for the treatment of refractory ligament disorders. Peptide Development Labs operates with established GMP operating systems, regulatory frameworks, and clinical-support infrastructure transferred from its parent company to advance its preclinical pipeline. The company is led by an experienced management team with deep expertise in pharmaceutical development and manufacturing.

Modalities: PeptidesBiologic
Industry: Biotech

Beyond the preview

Go deeper on Peptide Development Labs.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Peptide Development Labs.

Explore the full profile